Comparison of chlorzoxazone one-sample methods to estimate CYP2E1 activity in humans

European Journal of Clinical Pharmacology

Volumn 59, Issue 10, 2003, Pages 775-778

  Kramer, Iza ^a   Dalhoff, Kim ^a   Clemmesen, Jens O ^b   Loft, Steffen ^c   Poulsen, Henrik E ^a  

^a Rigshospitalet   (Denmark)

^b UNIVERSITY OF COPENHAGEN   (Denmark)

^c UNIVERSITY OF COPENHAGEN   (Denmark)

Author keywords

Chlorzoxazone; CYP2E1; Single sample clearance

Indexed keywords

BIOLOGICAL MARKER; CHLORZOXAZONE; CYTOCHROME P450 2E1; DRUG METABOLITE;

ADULT; ANALYTIC METHOD; ANAPHYLAXIS; AREA UNDER THE CURVE; ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; DRUG ACTIVITY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; ENZYME ACTIVITY; HUMAN; HUMAN EXPERIMENT; KIDNEY FUNCTION; MALE; NORMAL HUMAN; PRIORITY JOURNAL; RELIABILITY;

ADMINISTRATION, ORAL; ADULT; AREA UNDER CURVE; CHLORZOXAZONE; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; CYTOCHROME P-450 CYP2E1; HUMANS; MALE; METABOLIC CLEARANCE RATE; TIME FACTORS;

EID: 0346731058     PISSN: 00316970     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00228-003-0695-y     Document Type: Article

References (13)

1. Lucas D, Ferrara R, Gonzalez E, Bodenez P, Albores A, Manno M et al (1999) Chlorzoxazone, a selective probe for phenotyping CYP2E1 in humans. Pharmacogenetics 9:377-388
2. 450 IIE1. Chem Res Toxicol 3:566-573
3. 450 2E1. Clin Pharmacol Ther 53:643-650
4. 450 induction in alcoholic patients by chlorzoxazone pharmacokinetics. Biochem Pharmacol 47:1503-1508
5. Bachmann K, Sarver JG (1996) Chlorzoxazone as a single sample probe of hepatic CYP2E1 activity in humans. Pharmacology 52:169-177
6. Kim RB, O'Shea, Wilkinson GR (1995) Interindividual variability of chlorzoxazone 6-hydroxylation in men and women and its relationship to CYP2E1 genetic polymorphisms. Clin Pharmacol Ther 57:645-655
7. Stewart JT, Carter HK (1986) High-performance liquid chromatography with electrochemical detection of chlorzoxazone and its hydroxymetabolite in serum using solid-phase extraction. J Chromatogr 380:177-183
8. Bland JM, Altman DG (1986) Statistical methods for assessing agreement between two methods of clinical measurement. Lancet 8:307-310
9. Døssing M, Vølund A, Poulsen HE (1983) Optimal sampling times for minimum variance of clearance determination. Br J Clin Pharmacol 15:231-235
10. O'Shea D, Davis NS, Kim RB, Wilkinson GR (1994) Effect of fasting and obesity in humans on the 6-hydroxylation of chlorzoxazone: a putative probe of CYP2E1 activity. Clin Pharmacol Ther 56:359-367
11. 450 2E1 as assessed by the rate of chlorzoxazone hydroxylation in alcoholics during the withdrawal phase. Alcohol Clin Exp Res 19:362-366
12. 450 2E1 in chlorzoxazone 6-hydroxylation. Drug Metab Dispos 23:438-440
13. 450 2E1: choice of dose and phenotypic trait measure. J Clin Pharmacol 38:82-89